Pharmaceutical

Eli Lilly doubles down on Oblique partnership for antibody generation

The two companies have expanded their agreement first inked in 2023, with a second ‘high-value target’ now in the crosshairs.

Aug 25, 2024 - 04:00
Eli Lilly doubles down on Oblique partnership for antibody generation
The two companies have expanded their agreement first inked in 2023, with a second ‘high-value target’ now in the crosshairs.
Read the original article

Tags:

Previous Article

AstraZeneca may pull plug on UK vaccine manufacturing plans

Next Article

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools

STAT+: FDA’s warning to J&J’s Abiomed signals a crackdo...

Oct 16, 2023

Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case

Genentech review of Tessier-Lavigne paper finds no evid...

Apr 7, 2023

ESMO 2023: Mirati’s Krazati and immuno-oncology combo to shape first-line NSCLC

ESMO 2023: Mirati’s Krazati and immuno-oncology combo t...

Oct 23, 2023